Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

Inclusion criteria: * Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy * Patient who have given their written consent Exclusion criteria: * Current participation in a clinical trial for the second-line treatment of prostate cancer * Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity * Patients having already started a second line treatment The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.